What is oncimmunes technology? The company’s proprietary technology platform, EarlyCDT® is extensively validated for all types of lung cancer and for hepatocellular carcinoma (liver cancer). Oncimmune is helping to lead the advancement of early cancer detection across a range of solid tumour types.Why oncimmune immunoinsights? Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.What is oncimmunes collaboration with roche and university medical center utrecht? Oncimmune's collaboration with Roche and University Medical Center Utrecht demonstrates the utility of autoantibodies in methotrexate and tocilizumab treatment selection. “By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.”How can i contact immuneti customer support? We'd love to hear from you. The Immuneti team is always available to provide the best in customer support. Please fill out the form or email us directly at [email protected] . For press related inquiries please contact [email protected] .
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported